Table 3.
Sex-specific results of key trials of antihypertensive treatments (in alphabetical order).
| Trial | Total n | Proportion of women | Sex-specific results | Benefits to women or men | Reference |
|---|---|---|---|---|---|
| ACCOMPLISH | 11,506 | 39.5% | The results did not reach significance for females | – | (134) |
| ALLHAT | 33,357 | 47% | Lisinopril was found to be less effective in preventing stroke in women than chlorthalidone and amlodipine | – | (135) |
| ANBP-2 | 6,083 | 51.0% | Enalapril had a beneficial effect compared to a diuretic only in men | – | (136) |
| HOPE | 9,297 | 26.7% | Equal benefits in the prevention of major CV events for men and women | = | (137) |
| HOT | 18,790 | 47% | A reduction of diastolic BP <80 mm Hg was associated with a significant reduction of myocardial infarctions in women, but not in men | + | (138) |
| LIFE | 9,193 | 53.9% | It was more difficult to induce regression of LVH in women (according to the ECG criteria) | – | (139) |
| VALUE | 15,245 | 42.4% | In women, amlodipine-based treatment was more effective in the prevention of composite cardiac endpoint than valsartan-based | + | (111) |
+, results are in favor of women; =, results are neutral; –, results are in favor of men.